您当前的位置: 首页 > 资源详情

Biospace,8月23日,FDA Fully Approves First COVID-19 Vaccine

编译者:YUTING发布时间:Aug 28, 2021点击量:106 来源栏目:最新研究

The U.S. Food and Drug Administration (FDA) has granted the Pfizer-BioNTech COVID-19 vaccine full approval. Up to this point it was being distributed under an Emergency Use Authorization (EUA). Many expect the full approval will lead to vaccine mandates, as that was one of the obstacles to it for many organizations.

“The vaccine has been known as the Pfizer-BioNTech COVID-19 vaccine, and will now be marketed as Comirnaty, for the prevention of COVID-19 disease in individuals 16 years of age and older,” the FDA stated. “The vaccine also continues to be available under emergency use authorization, including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.”

In the U.S., more than 170 million people have been fully vaccinated against COVID-19, and more than 92 million of them received the Pfizer-BioNTech vaccine, the first to be granted EUA in the U.S. in December 2020. EUA for the Moderna vaccine followed shortly afterwards, and then the Johnson & Johnson one-shot vaccine was granted EUA in February 2021.

“For business and universities that have been thinking about putting vaccine requirements in place in order to create safer spaces for people to work and learn, I think that this move from the FDA, when it comes, will actually help them to move forward with those kinds of plans,” U.S. Surgeon General Vivek Murthy said yesterday on CNN’s State of the Union.

EUA is granted to medical products for use during an emergency, and once that emergency is over, according to the FDA, “then any EUA(s) issued based on that declaration will no longer remain in effect.” The state of emergency was declared by former Health and Human Services Secretary Alex Azar on January 31, 2020, and has been renewed several times, most recently in late July.

Moderna has started its application for full approval. J&J has yet to file for full FDA approval.

A Kaiser Family Foundation poll conducted in June found that 31% of unvaccinated people claimed they would be more likely to get a COVID-19 vaccine once one receives full FDA approval.

Acting FDA Commissioner Janet Woodcock stated, “While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.”

Paul Offit, a voting member of the FDA’s Vaccines and Related Biological Products Advisory Committee, noted that full approval is “more psychological than anything else. I mean you already have more than 320 million doses administered that are out there. The vaccines already have an enormous safety and efficacy profile.”

Some major corporations, such as Walt Disney and Walmart, have already mandated that some or all of their staff must get fully vaccinated this fall. Others have expressed hesitation in their ability to mandate a vaccine that is not fully approved, which would no longer be a stumbling block. The Pentagon has said it would make vaccines mandatory for service members “no later” than the middle of September, but that they would mandate it earlier if the FDA granted full approval.

提供服务:导出本资源
  1. 1 Nature,11月10日,Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility
  2. 2 11月10日_研究人员分析宿主基因对COVID-19严重程度和易感性的影响
  3. 3 11月11日_新冠药物Remestemcel-L二期临床的中期分析结果积极
  4. 4 11月11日_CDC呼吁制定通用口罩规定以减少新冠传播
  5. 5 SSRN,2月20日,Dynamics of the Latest 2019 Novel Coronavirus Disease Epidemic in China: A Descriptive Study
  6. 6 SSRN,2月20日,Mental Health Problems and Social Media Exposure During COVID-19 Outbreak
  7. 7 SSRN,2月20日,Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources
  8. 8 SSRN,2月20日,Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China
  9. 9 Nature,11月10日,Mobility network models of COVID-19 explain inequities and inform reopening
  10. 10 1月27日_Nature报道中国新型冠状病毒最新研究进展:病毒传播速度有多快?
  1. 1 10月11日_SARS-CoV-2变体对mRNA疫苗诱导的免疫反应的影响
  2. 2 10月11日_SARS-CoV-2变体对mRNA疫苗诱导的免疫反应的影响
  3. 3 Medicalxpress,10月11日,Vaccines prevent severe COVID, even from Delta: study
  4. 4 10月11日_疫苗接种可预防严重COVID-19
  5. 5 PR Newswire,10月11日,INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
  6. 6 10月11日_INOVIO扩展其COVID-19疫苗INO-4800的3期研究
  7. 7 ACCESSWIRE,10月11日,NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
  8. 8 10月11日_NV-CoV-2具有广谱的抗冠状病毒活性
  9. 9 CIDRAP,10月11日,Merck applies for approval of first COVID-19 antiviral pill
  10. 10 10月11日_默沙东向FDA申请首款COVID-19抗病毒药丸的EUA

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190